Stoke Therapeutics, Inc. 8K

Stoke Therapeutics filed a Form 8-K to furnish a legal opinion supporting the validity of up to $200 million of common stock issuable under its at-the-market offering program with Cantor Fitzgerald & Co.

Stoke Therapeutics, Inc. obtained a legal opinion from Fenwick & West LLP, dated August 3, 2026, confirming that up to $200 million of its common stock to be issued from time to time as "Placement Shares" under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., pursuant to its automatically effective Form S-3ASR shelf registration and related prospectus supplement, will be validly issued, fully paid and nonassessable when sold as contemplated, and filed this opinion as an exhibit to a Current Report on Form 8-K in connection with the at-the-market offering program.

Filing Facts

CIK

1623526

Ticker

STOK

Form

8K

Source Type

fda

Accession

0001193125-26-330804

Alert Tier

6